Atlas Trials

Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents

Clinical trial NCT03567291 · TERMINATED

Trial details

NCT number
NCT03567291
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Tourette Syndrome
Start date
2018-05-25
Primary completion
2020-05-15
Enrollment
228

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.